The weight-loss drug Wegovy reduced the risk of strokes, heart attacks and other cardiovascular problems by 20 percent among overweight people with a history of heart disease, its manufacturer said Tuesday.
such as Wegovy, can provide important health benefits, not just cosmetic ones. Obesity should be treated as a serious illness given its contribution to other problems such as heart disease, specialists said.Wegovy, and Medicare is barred from paying for weight-loss medications. With Wegovy costing more than $1,300 a month, the lack of insurance coverage has put the drug out of reach for many people.
Steven Nissen, a Cleveland Clinic cardiologist, noted that while Tuesday’s announcement is promising, he wants to see the full results. Ozempic is approved by the Food and Drug Administration for treating Type 2 diabetes, although doctors commonly prescribe it for weight loss.Mounjaro, which is also called tirzepatide, mimics GLP-1 but also targets a second, closely related hormone called GIP, which also stimulates insulin production. Lilly is seeking FDA approval to market Mounjaro to manage weight loss as well as diabetes.
Martin Holst Lange, executive vice president for development at Novo Nordisk, called the Select trial a “landmark study” in the company’s statement.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Weight-Loss Drug Wegovy Cuts Heart Attack, Stroke Risk by 20% in New StudyAnti-obesity drug Wegovy not only helped people lose weight but also reduced their risk of suffering heart attacks, strokes and cardiovascular deaths by 20% in a study
Weiterlesen »
Novo's weight-loss drug Wegovy cuts risk of heart disease by 20% - trial dataNovo Nordisk's obesity drug Wegovy has shown a clear medical benefit, reducing the risk of heart disease by 20% according to a large late-stage study. The positive results have boosted the Danish drugmaker's hopes of repositioning Wegovy as more than just a lifestyle drug.
Weiterlesen »
Novo weight-loss drug Wegovy shows heart benefit in trialNovo Nordisk announced that a trial has revealed that patients taking the weight-loss drug Wegovy had a 20% lower risk of heart attack, stroke, or death from heart disease compared to those on a placebo. This finding gives hope to Novo Nordisk in expanding the perception of Wegovy beyond being just a lifestyle drug.
Weiterlesen »
Psychiatrists Prescribe Wegovy for Medication-Induced Weight GainPsychiatrists are increasingly prescribing the popular weight-loss drug Wegovy to patients who gain weight from medicines used to treat mental disorders, such as schizophrenia or bipolar disorder.
Weiterlesen »
Wegovy Reduces Risk of Heart Attack and Stroke in Major Cardiovascular TrialA major clinical trial has shown that the weight loss drug Wegovy can reduce the risk of heart attack, stroke, or heart disease-related death by 20% in people with cardiovascular disease, marking the first time a weight loss drug has demonstrated such protective effects.
Weiterlesen »
Obesity drug Wegovy found to prevent heart attacks, strokesAccording to Novo Nordisk, people on Wegovy were 20% less likely to develop serious cardiovascular problems for up to five years when compared to placebo. The active ingredient in Wegovy is called semaglutide. It’s a synthetic version of our body’s GLP-1 hormone, which plays an important role in regulating our metabolism. GLP-1 drugs promote insulin secretion and have been approved to help manage type 2 diabetes for over a decade.
Weiterlesen »